psychiatric disorders (schizophrenia, addiction, OCD, ADHD, depression), fMRI, THC, cannabinoid system
Conditions
Interventions
1. THC will be inhaled (5 times: first dose 6 mg, upload doses 1 mg) by means of a Vulcano Vaporizer
2. Functional MRI scans will be performed during cognitive tasks.
Sponsors
Prof. Dr. N.F. Ramsey
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy control or Diagnosed with one psychiatric disorder, according to DSM-IV criteria, axis I: A. Schizophrenia; B. Depression; C. ADHD; D. Addiction to nicotine (heavy smokers); E. OCD. 2. Male; 3. Current occasional cannabis use since at least one year (<1/week and ¡Ý 4/year) without known negative implications (e.g. bad trip, cannabis-induced psychosis); 4. Right-handedness, assessed with the Edinburgh Handedness Inventory (Oldfield, 1971); 5. Written informed consent of the subject.
Exclusion criteria
Exclusion criteria: 1. Clinical significant abnormalities, except for the predetermined psychiatric disorder; 2. For healthy controls, first degree relatives with a psychiatric disorder according to DSM IV; 3. Impaired physical health evaluated by medical history and physical (including neurological) examination; 4. Current diagnosis of abuse of drugs or alcohol (according to DSM-IV) except for tobacco; 5. Past but recent diagnosis of abuse of drugs or alcohol other than tobacco, i.e. within 12 months preceding study inclusion; 6. Body Mass Index (B.M.I.) 28 kg/m2; 7. Any subject who received any investigational medication within 90 days prior to the start of the study or who is scheduled to receive an investigational drug; 8. The use of any medication within three weeks prior to the start of the study, except for paracetamol and medication for the psychiatric disorder; 9. Blood donation within 3 months before the start of the study; 10. Claustrophobia; 11. Metal objects in or around the body (braces, pacemaker, metal fragments).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The main study parameter is the blood oxygen level dependent (BOLD) signal. | — |
Secondary
| Measure | Time frame |
|---|---|
| Behavioral parameters (two sets of visual analogue scales), cerebral blood flow (measured with Arterial Spin Labeling), the concentration of plasma THC and its main metabolites, and the performance on neuropsychological tests will be measured. | — |
Contacts
Public ContactH.H. Hell, van
Outcome results
None listed